These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29752021)

  • 1. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens.
    De Sanctis F; Sandri S; Martini M; Mazzocco M; Fiore A; Trovato R; Garetto S; Brusa D; Ugel S; Sartoris S
    Vaccine; 2018 Jun; 36(25):3708-3716. PubMed ID: 29752021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of murine tumour growth through CD8
    Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
    Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.
    Liu XQ; Jiang R; Li SQ; Wang J; Yi FP
    Asian Pac J Cancer Prev; 2015; 16(2):571-8. PubMed ID: 25684489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
    Mikyšková R; Štěpánek I; Indrová M; Bieblová J; Šímová J; Truxová I; Moserová I; Fučíková J; Bartůňková J; Špíšek R; Reiniš M
    Int J Oncol; 2016 Mar; 48(3):953-64. PubMed ID: 26718011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity.
    Mukhopadhaya A; Mendecki J; Dong X; Liu L; Kalnicki S; Garg M; Alfieri A; Guha C
    Cancer Res; 2007 Aug; 67(16):7798-806. PubMed ID: 17699785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells.
    Brusa D; Migliore E; Garetto S; Simone M; Matera L
    Prostate; 2009 Sep; 69(12):1343-52. PubMed ID: 19496055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.
    Ricupito A; Grioni M; Calcinotto A; Hess Michelini R; Longhi R; Mondino A; Bellone M
    Cancer Res; 2013 Jun; 73(12):3545-54. PubMed ID: 23539449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.
    Hwang EC; Lim MS; Im CM; Kwon DD; Lee HJ; Nguyen-Pham TN; Lee YK; Lee JJ
    Scand J Immunol; 2013 Feb; 77(2):117-24. PubMed ID: 23126536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
    Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
    Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
    Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
    Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy.
    Orange DE; Jegathesan M; Blachère NE; Frank MO; Scher HI; Albert ML; Darnell RB
    Prostate Cancer Prostatic Dis; 2004; 7(1):63-72. PubMed ID: 14999241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.
    Nam GH; Lee EJ; Kim YK; Hong Y; Choi Y; Ryu MJ; Woo J; Cho Y; Ahn DJ; Yang Y; Kwon IC; Park SY; Kim IS
    Nat Commun; 2018 Jun; 9(1):2165. PubMed ID: 29867097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.